Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older.
• People whose general health and ability to carry out daily activities meets a minimum functional level (confirm with trial site).
• People who have been diagnosed with marginal zone lymphoma (MZL) — including splenic, nodal, or extranodal types — confirmed through a tissue biopsy.
• People whose lymphoma currently needs treatment.
• People who have not previously received systemic (whole-body) drug treatment for MZL, except for antibiotics used to treat certain bacterial infections (H. pylori, C. psittaci, or B. burgdorferi) or antiviral treatment for hepatitis C — prior surgery, spleen removal, or radiation therapy alone is acceptable, provided at least 14 days have passed since radiation ended.
• People with gastric MALT lymphoma who have tested negative for H. pylori, or whose lymphoma did not respond to H. pylori treatment.
• People with localised MALT lymphoma who are not suitable for radiation therapy, have declined it, or for whom it has not worked (with at least 14 days passed since radiation ended).
• People whose blood counts and organ function meet the required minimum levels — including white blood cells, platelets, haemoglobin, liver function, kidney function, and blood clotting measures (confirm specific values with trial site).
• People with a life expectancy of more than 3 months, in the opinion of the treating doctor.
• Women who are confirmed not to be pregnant, or who are post-menopausal or have been surgically sterilised, based on specific age-related criteria (confirm with trial site).
• People who are willing and able to use highly effective contraception during the trial, and who do not plan to become pregnant or breastfeed within 1 month of the last dose of pirtobrutinib, or within 12 months of the last rituximab infusion.
• People who are able to swallow tablets whole.
• People who are able to read, understand, and sign an informed consent form, either themselves or through a legal representative.

Who may not be able to join:

• People who require blood-thinning treatment with warfarin or another vitamin K antagonist medication.
• People who have received a live-virus vaccine within 28 days before starting the trial, or who will need one at any point during the trial.
• People who have a condition that significantly affects how the gut absorbs medication.
• People with a history of abnormal or excessive bleeding.
• People who have had major surgery within 4 weeks before starting the trial, or who have not fully recovered from major surgery.
• People with another cancer diagnosis that, in the doctor's opinion, could negatively affect their safety or participation in the trial.
• People whose lymphoma has spread to the brain or central nervous system.
• People with serious uncontrolled ongoing illnesses, including certain heart conditions such as severe heart failure, uncontrolled irregular heartbeat, unstable chest pain or heart attack within the past 3 months, stroke or brain bleed within the past 6 months, abnormal heart rhythm readings on an ECG, or significantly reduced heart pumping function within the past 12 months (confirm specific thresholds with trial site).
• People with a known HIV infection.
• People with active hepatitis B or active hepatitis C infection (note: people with past resolved hepatitis B or cleared hepatitis C may still be considered eligible — confirm with trial site).
• People with a known active cytomegalovirus (CMV) infection.
• People with an active, uncontrolled autoimmune condition affecting blood cells (such as autoimmune haemolytic anaemia or immune thrombocytopenic purpura) for which treatment was newly started or increased within the 4 weeks before joining the trial.
• People with medical, psychiatric, or cognitive conditions that would prevent them from understanding the study, giving consent, or following the study requirements.
• People who have previously had a severe allergic reaction to the study drugs or any of their ingredients.

Important: Always verify eligibility with the trial site directly before applying.